Ptc Therapeutics (PTCT) Common Equity (2012 - 2026)

Ptc Therapeutics' Common Equity history runs 15 years deep, the most recent figure standing at -$165.4 million for Q2 2026.

• In Q2 2026, Common Equity rose 19.94% year-over-year to -$165.4 million; the TTM figure through Jun 2026 stood at -$165.4 million (up 19.94% YoY), while the FY2025 annual figure was -$205.3 million, up 81.3% from the prior year.
• Common Equity for Q2 2026 stood at -$165.4 million, up from -$180.5 million in the prior quarter.
• The five-year high for Common Equity was -$90.6 million in Q1 2022, with the low at -$1.1 billion in Q4 2024.
• The 5-year median for Common Equity is -$287.0 million (2022), against an average of -$472.2 million.
• The sharpest annual moves came in 2022 and 2025: Common Equity sank 24236.72% in 2022, then soared 85.23% in 2025.
• Ptc Therapeutics' Common Equity stood at -$347.1 million in 2022, then tumbled by 135.84% to -$818.6 million in 2023, then tumbled by 34.15% to -$1.1 billion in 2024, then surged by 81.3% to -$205.3 million in 2025, then rose by 19.46% to -$165.4 million in 2026.
• Business Quant data shows PTCT's Common Equity at -$165.4 million in Q2 2026, -$180.5 million in Q1 2026, and -$205.3 million in Q4 2025.